Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis

Contributed by: PR Newswire

Tags

Argo-Novartis-RNAi

More Like This

PR Newswire associated0

Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction

Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics

Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension

PR Newswire associated0

Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference

PR Newswire associated0

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

PR Newswire associated0

Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs

Business Wire logo

Novotech Report Reveals Growth in siRNA Research: Over 150 Industry-Sponsored Clinical Trials Conducted from 2020 to 2024

PR Newswire associated0

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology